Results 11 to 20 of about 169,450 (313)

Taking Biologics for Granted? Takings, Trade Secrets, and Off-Patent Biological Products [PDF]

open access: yes, 2005
Biologics are complex medicines which are often genetically engineered, and which are sure to play an important role in curing some of humankind\u27s worst diseases. Not surprisingly, generic companies want a part of the biologic market. The FDA believes
Bergman, Karl-Olof   +2 more
core   +3 more sources

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

open access: yes, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells

open access: yesOncoImmunology, 2019
Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20–40% of patients to generate anti-tumor immune responses.
Maxine Bauzon   +5 more
doaj   +1 more source

Engineered Fc-glycosylation switch to eliminate antibody effector function

open access: yesmAbs, 2020
Antibodies mediate effector functions through Fcγ receptor (FcγR) interactions and complement activation, causing cytokine release, degranulation, phagocytosis, and cell death. They are often undesired for development of therapeutic antibodies where only
Qun Zhou   +13 more
doaj   +1 more source

Comprehensive modeling of cell culture profile using Raman spectroscopy and machine learning

open access: yesScientific Reports, 2023
Chinese hamster ovary (CHO) cells are widely utilized in the production of antibody drugs. To ensure the production of large quantities of antibodies that meet the required specifications, it is crucial to monitor and control the levels of metabolites ...
Hiroki Tanemura   +5 more
doaj   +1 more source

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

open access: yesJournal for ImmunoTherapy of Cancer, 2022
Background Cancer immunotherapy has revolutionized cancer treatment. However, considering the limited success of immunotherapy to only some cancer types and patient cohorts, there is an unmet need for developing new treatments that will result in higher ...
Frank Nestle   +16 more
doaj   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

open access: yesNature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang   +12 more
doaj   +1 more source

Engineering an anti-CD52 antibody for enhanced deamidation stability

open access: yesmAbs, 2019
Deamidation evaluation and mitigation is an important aspect of therapeutic antibody developability assessment. We investigated the structure and function of the Asn-Gly deamidation in a human anti-CD52 IgG1 antibody light chain complementarity ...
Huawei Qiu   +11 more
doaj   +1 more source

Biological membranes [PDF]

open access: yesEssays in Biochemistry, 2015
Biological membranes allow life as we know it to exist. They form cells and enable separation between the inside and outside of an organism, controlling by means of their selective permeability which substances enter and leave. By allowing gradients of ions to be created across them, membranes also enable living organisms to generate energy.
openaire   +2 more sources

Home - About - Disclaimer - Privacy